Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Solid Biosciences Inc SLDB

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3... see more

Recent & Breaking News (NDAQ:SLDB)

Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer

GlobeNewswire January 9, 2023

Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 9, 2023

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 5, 2022

Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement

GlobeNewswire December 5, 2022

Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio

GlobeNewswire December 1, 2022

Solid Biosciences to Participate at the Piper Sandler 34th Annual Healthcare Conference

GlobeNewswire November 22, 2022

EQUITY ALERT: The M&A Class Action Firm Continues Investigating the Merger - HVBC, IMRA, SLDB, SMBC

PR Newswire November 17, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JVA, SLDB, FCRD, SPNE

PR Newswire November 15, 2022

SOLID BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Solid Biosciences Inc. - SLDB

Business Wire November 12, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JVA, SLDB, FCRD, SPNE

PR Newswire November 10, 2022

Solid Biosciences Provides Third Quarter 2022 Business Update and Financial Results

GlobeNewswire November 10, 2022

Solid Biosciences Announces a 1-for-15 Reverse Stock Split

GlobeNewswire October 27, 2022

Solid Biosciences Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle

GlobeNewswire October 17, 2022

Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results at World Muscle Society 2022 Congress Demonstrating Improvements in Ambulatory Function

GlobeNewswire October 13, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SLDB, RFP, SBTX, SGFY, COWN

PR Newswire October 3, 2022

SOLID BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Solid Biosciences Inc. - SLDB

Business Wire September 30, 2022

SLDB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Solid Biosciences Inc. Is Fair to Shareholders

Business Wire September 30, 2022

Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement

GlobeNewswire September 30, 2022

Solid Biosciences to Participate at Upcoming Investor Conferences

GlobeNewswire September 29, 2022

Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results

GlobeNewswire August 11, 2022